3月4日 - ** 券商BofA Global Research将制药商艾伯维ABBV.N的目标价从200美元上调至223美元，较该股上次收盘价上涨5.4%。
** 维持 "中性 "评级
** 评级上调的部分 原因是ABBV本周早些时候 与丹麦生物技术公司Gubra
** 券商称，ABBV预计，作为一种独立产品， 该产品可减轻15%至20%的体重，与 GLP-1药物相比 ，其耐受性更好，瘦肉损失更少。
** 尽管进入肥胖症药物市场较晚的企业可能难以与现有的诺和诺德NOVOb.CO和礼来LLY.N竞争，但一套产品和/或差异化将有所帮助，BofA称
** 股价在过去 12 个月中上涨了 18.2
(为便利非英文母语者，路透将其报导自动化翻译为数种其他语言。由于自动化翻译可能有误，或未能包含所需语境，路透不保证自动化翻译文本的准确性，仅是为了便利读者而提供自动化翻译。对于因为使用自动化翻译功能而造成的任何损害或损失，路透不承担任何责任。)
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.